Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Most Americans with allergies should be safe to get Pfizer-BioNTech vaccine: FDA

Published 12/12/2020, 12:45 PM
Updated 12/12/2020, 12:50 PM
© Reuters. FILE PHOTO: A vial of the Pfizer/BioNTech COVID-19 vaccine is seen at the Royal Victoria Hospital in Belfast

By Michael Erman

(Reuters) - Top U.S. Food and Drug Administration regulators said on Saturday that most Americans with allergies should be safe to receive the COVID-19 vaccine developed by Pfizer Inc (NYSE:PFE) and Germany's Biotech SE.

The FDA, which authorized the nation's first COVID-19 vaccine on Friday night, said that only people who have previously had severe allergic reactions to vaccines or ingredients in this particular vaccine should avoid getting the shot.

"We're telling people that unless they've had a severe allergic reaction to the vaccine, or one of its components, they can receive it," Dr. Peter Marks, director of the FDA division that authorized the vaccine, said at a press conference.

After Britain began inoculations this week, two people with severe allergies reported side effects and the British medicine regulator advised that anyone with a history of anaphylaxis to a medicine or food should not get the Pfizer-BioNTech vaccine.

"About 1.6% of the population has had a severe allergic reaction of some sort or another to a food or some environmental aspect and we would really not like to have that many people not be able to receive the vaccine," Marks said.

The vaccine is seen as a key tool in stemming the coronavirus pandemic that has killed nearly 300,000 people in the United States.

The FDA advised people with allergies to consult with their doctors to make sure that they are not allergic to any of the component of the vaccine.

Pfizer executives said on Friday that there had been no cases of severe allergic reactions to the vaccine during its nearly 44,000 volunteer late-stage clinical trial. That trial excluded people with a history of severe allergic reactions to any vaccine or to the Pfizer-BioNTech vaccine's ingredients.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

They said there were no anaphylactic episodes related to the vaccine in the trial, which did include about 6,000 participants respectively in both the vaccine and placebo groups with a range of allergic conditions such as pollen allergies and food allergies. Those participants had a history of symptoms including anaphylaxis.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.